Catherine C. Coombs, MD


Acalabrutinib in CLL: Insights from the ELEVATE TN and ASCEND Trials

August 12th 2022

Highlighting the ELEVATE TN and ASCEND clinical trials, panelists share expert insights into the next-generation BTK inhibitor acalabrutinib for CLL.

Treatment Overview: Chronic Lymphocytic Leukemia

August 12th 2022

Catherine C. Coombs, MD, leads the faculty in a discussion of the current treatment landscape for CLL with a review of considerations for patients with high-risk or relapsed/refractory disease.

Advancements on the Horizon in Mantle Cell Lymphoma

August 5th 2022

Thought leaders in hematologic malignancies reflect on studies of ROR1 and share perspectives on advancements on the horizon for mantle cell lymphoma.

Strategies for Sequencing and Combining Therapies in MCL

August 5th 2022

A panel of distinguished faculty builds a lively conversation on the emergence of pirtobrutinib and its effect on treatment sequencing strategies in MCL as well as the overall role of doublet and triplet regimens.

CAR T-Cell Therapy in R/R MCL

July 29th 2022

Michael Wang, MD, guides the panel in a discussion on CAR T-cell therapy for relapsed/refractory MCL including a summary of key takeaways from the ZUMA-2 trial and a conversation on real-world vs clinical trial data.

BTK Inhibitors in Relapsed/Refractory MCL and Treatment Selection

July 29th 2022

Panelists discuss treatment considerations in the use of BTK inhibitors for relapsed/refractory mantle cell lymphoma, with Matthew S. Davids, MD, MMSc, reviewing strategies for the management of AEs.

Second-line Therapies in MCL: Regimens With BTK Inhibitors and BCL-2 Targeting Therapies

July 22nd 2022

Key opinion leaders in mantle cell lymphoma discuss the emergence of more effective novel therapies such as BTK inhibitors and BCL-2 inhibitors and whether there is a continued role for lenalidomide-based regimens.

Mantle Cell Lymphoma Maintenance Strategies

July 22nd 2022

A panel of experts in hematologic malignancies discusses maintenance strategies for mantle cell lymphoma with particular emphasis on treatment considerations related to the COVID-19 pandemic and real-world data.

Factors for Consideration in Treatment Decision-making for MCL

July 15th 2022

Focusing on the differences in treatment considerations between younger and older patients, Michael Wang, MD, discusses the current treatment landscape in mantle cell lymphoma.

Disease Overview: Mantle Cell Lymphoma

July 15th 2022

Anthony R. Mato, MD, MSCE, introduces the panel, and Alexey V. Danilov, MD, PhD, provides an overview of the incidence, presentation, pathologic features, and treatment landscape for mantle cell lymphoma.

Optimizing the Treatment of CLL With Novel Therapies

March 14th 2022

Oncologist-hematologists discuss the outlook for treating patients with chronic lymphocytic leukemia with newer novel therapies.

CAR T-Cell Therapies in CLL

March 14th 2022

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

PI3K Inhibitors for CLL

March 7th 2022

A comparison of 3 PI3K inhibitors—idelalisib, duvelisib, and umbralisib—as treatment for chronic lymphocytic leukemia.

Noncovalent BTK Inhibitors in CLL

March 7th 2022

Recommendations for applying information from clinical trials presented at oncology and hematology conferences in 2021 into routine clinical practice when managing patients with chronic lymphocytic leukemia.

Novel Therapies for CLL: Sequencing Strategies

February 28th 2022

Factors that impact decisions for frontline and subsequent lines of therapy for patients with chronic lymphocytic leukemia.

Treating CLL With Anti-CD20 Antibody Regimens

February 21st 2022

Recommendations for combining an anti-CD20 antibody with a Bruton tyrosine kinase inhibitor or venetoclax in doublet or triplet regimens for the treatment for chronic lymphocytic leukemia (CLL).

Chemotherapy-Free Regimens as Frontline Therapy in CLL

February 21st 2022

Key takeaways of the CLL13 (GAIA) clinical trial based on highlights presented at ASH 2021.

Fixed-Duration Therapy in Frontline CLL: Venetoclax Plus Obinutuzumab

February 14th 2022

The rationale for investigating the fixed-duration, all-oral combination regimen of venetoclax with obinutuzumab as treatment for chronic lymphocytic leukemia.

Fixed-Duration Therapy in Frontline CLL: Ibrutinib Plus Venetoclax

February 7th 2022

Key takeaways from the CAPTIVATE and GLOW trials of ibrutinib plus venetoclax as fixed-duration frontline therapy for chronic lymphocytic leukemia.

Acalabrutinib as Frontline Therapy for CLL

January 31st 2022

Features that distinguish acalabrutinib, a second-generation Bruton tyrosine kinase inhibitor, from ibrutinib as frontline therapy for patients with chronic lymphocytic leukemia.